Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02668588
Other study ID # LF-PB/14/05
Secondary ID
Status Completed
Phase Phase 2
First received January 27, 2016
Last updated February 1, 2017
Start date October 22, 2015
Est. completion date July 19, 2016

Study information

Verified date February 2017
Source Chemi S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicentre, double blind, randomized placebo controlled trial to assess the effect of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node Dissection (ALND).

Recruited patients will be randomly assigned to receive LF-PB 30 mg or placebo.


Description:

The study will randomize between 24 and 72 subjects that received an ALND. A staged adaptive design is employed with two intermediate analyses and a final analysis. The first interim analysis at 24 treated subjects (at least 12 in each group) and the second at 48 treated subjects (at least 24 in each group).


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date July 19, 2016
Est. primary completion date July 19, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed informed consent form;

- Undergoing breast cancer surgery with axillary lymph node dissection during the current clinical trial;

- Negative serum pregnancy test for women of childbearing potential;

- Aspartate aminotransferase and alanine aminotransferase < 2 x the upper limit of normal;

- ECOG PS = 1.

Exclusion Criteria:

- Previous axillary surgery on the same armpit (sentinel lymph node surgery is not exclusionary);

- Previous radiotherapy within five years from study drug administration on the same armpit undergoing surgery in this study;

- Concomitant participation to other clinical trial;

- Uncontrolled diabetes;

- Cholelithiasis;

- Human immunodeficiency virus or hepatitis B or C by screening serology;

- Uncontrolled hypothyroidism: if patient is being administered Eutirox/ Levothyroxine (or analogues) and levels of T3, T4 and TSH are confirmed to be within the normal ranges at screening, the patient can be enrolled in this study;

- Pregnant or lactating;

- Ascertained or presumptive hypersensitivity to the active principle and/or the ingredients of the study drug formulation;

- Corrected QT (using the Bazett formula, QTc) interval at screening or baseline > 450 msec (as the mean of 3 consecutive readings 5 minutes apart);

- Presence of any disease or use of concomitant medication known to increase the QT interval;

- Clinically significant or relevant abnormal medical history, vital sign, physical examination or laboratory evaluation finding;

- Corticosteroid treatment on a long-term basis (i.e. treatment for more than 3 consecutive days);

- Current or recurrent disease that could affect the results of the clinical or laboratory assessment required for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
extended release of octreotide
1 intramuscular injection of extended release of octreotide 30 mg
extended release of placebo
1 intramuscular injection of extended release of placebo

Locations

Country Name City State
Italy Az. Osp. Univ. Mater Domini Catanzaro Calabria
Italy Az. Osp. Univ. di Ferrara - Ospedale di Cona Ferrara Emilia Romagna
Italy IRCCS Azienda Ospedaliera Universitaria San Martino Genova Liguria
Italy Az.Osp. Univ. Policlinico di Modena Modena Emilia Romagna
Italy IRCCS Fondazione Pascale Naples Campania
Italy Az. Osp. Univ. di Parma Parma Emilia Romagna
Italy Az. Osp. Univ. Città Della Salute e Della Scienza di Torino Turin Piemonte

Sponsors (1)

Lead Sponsor Collaborator
Chemi S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of seromas requiring an aspiration Subjects will undergo an echography at the operated axilla at every scheduled visit till Day 28 or until seroma resolution, whichever occurs first. In case of seroma presence the investigator will decide if an aspiration is required; the decision will be based on the clinical investigator's evaluation.
In case of aspiration, the subject with seroma will be considered amenable for the statistical analysis of seroma incidence.
Day 28 post surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04496180 - Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy N/A
Completed NCT03665883 - Use of Diathermy Versus Blunt Dissection in TEP for Inguinal Hernia N/A
Completed NCT03650868 - The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery N/A
Completed NCT01454713 - Retrospective Analysis of Veritas in Breast Reconstruction N/A
Not yet recruiting NCT04471142 - Effectiveness of Compressive Bandage Use in Seroma Prevention N/A
Not yet recruiting NCT02967627 - VAC Dressings for Colorectal Resections N/A
Recruiting NCT03598712 - Local Compression Seroma DIminution Objective (CLODIS) Phase 3
Completed NCT04666051 - Fibrin Glue in Inguinal Lymphadenectomy N/A
Recruiting NCT01454167 - Acid Base and Electrolytes Patterns in Drains Operational Wounds and Its Relation to Complications N/A
Completed NCT01112735 - Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty Phase 2
Completed NCT00968318 - Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders N/A
Completed NCT03647930 - The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy N/A
Recruiting NCT05509829 - EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery N/A
Terminated NCT04818580 - Progressive Tension Sutures in Gender Affirming Mastectomy N/A
Withdrawn NCT02568085 - Trial Evaluating Use of Arista in Total Thyroidectomy N/A
Active, not recruiting NCT01942707 - Scarpa´s Fascia in the Formation of Seroma Post Abdominoplasty After Bariatric Surgery N/A
Recruiting NCT03167944 - Traditional Electrosurgery System Versus Low Thermal Tissue Dissection System for Total Mastectomy N/A
Recruiting NCT03190876 - Seroma Prevention After Body Contouring Procedures N/A
Completed NCT03590704 - Safety of the Use of Compressive Taping in Seroma N/A
Recruiting NCT04035590 - Seroma Reduction and Drain Free Mastectomy N/A